Reagent Proteins

Gradient Horizontal line
Reagent, pre-clinical and cGMP grade proteins available
Request Button

Innovative Solutions for Global Health


Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis (ranibizumab).


Our patented protein production platform, Pfenex Expression Technology, enables our ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enables the rapid delivery of protein products into clinical development and commercialization.


Pfenex is leveraging its technology platform for its own product pipeline, strain engineering services, and for scientists seeking reagents for research use.